Characteristics and Symptom Management of Progressive Supranuclear Palsy: A Multidisciplinary Approach

Ward, Constance

doi:10.1097/01376517-200608000-00007

Cited by 10 publications

(19 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…50,75,76 Better therapies will require addressing the many currently untreated symptoms and a better understanding of PSP pathophysiology. Given the relatively small number of patients with PSP compared with PD, we anticipate that advances in symptomatic and neuroprotective therapy will continue to take advantage of agents currently developed for use in PD.…”

Section: Multidisciplinary Approachmentioning

confidence: 99%

Progressive Supranuclear Palsy

Lubarsky

Juncos²

2008

The Neurologist

View full text Add to dashboard Cite

It is clear that PSP continues to be an under-recognized disorder with multilevel involvement of the neuraxis that helps differentiate it from other akinetic rigid syndromes such as PD. A greater appreciation of its atypical presentations, more attention to its neurobehavioral signs and better imaging techniques are some of the advances that will help facilitate earlier detection, which may reduce morbidity by helping anticipate early falls and minimizing unnecessary diagnostic procedures. Surgical approaches to PSP have been ineffective so far. Carefully targeted symptomatic treatment with drugs and other therapies is available and effective at reducing morbidity and improving quality of life.

show abstract

Section: Multidisciplinary Approachmentioning

confidence: 99%

Progressive Supranuclear Palsy

Lubarsky

Juncos²

2008

The Neurologist

View full text Add to dashboard Cite

show abstract

“…The extrapyramidal and ocular motility findings are reminiscent of progressive supranuclear palsy (PSP) 5. Hyperintensity of the corticospinal tracts on magnetic resonance images is an occasional finding in ALS and has been reported in atypical primary lateral sclerosis 6,7.…”

Section: Commentmentioning

confidence: 99%

Amyotrophic Lateral Sclerosis–Plus Syndrome With TAR DNA-Binding Protein-43 Pathology

McCluskey¹,

Elman²,

Martinez‐Lage³

et al. 2009

Arch Neurol

View full text Add to dashboard Cite

“…6,17 Patiënt A en B ontwikkelden beiden apathie gedurende het ziekteproces. Patiënt C onderschrijft de presentatie met frontale gedragsstoornissen en de verdenking FTD in het begin van het ziekteproces.…”

Section: Diagnoseunclassified

Progressieve Supranucleaire Verlamming. Interventie middels acetylcholineesteraseremmer?

Nijboer

Dautzenberg²

2009

GEEG

View full text Add to dashboard Cite

Progressive supranucleair palsy (PSP) is a serious neurologic disease which is seldom diagnosed due to its complexity. In 1996 international diagnostic criteria were developed by a group of experts, the diagnosis remains complicated. We describe three cases, which were followed in the period 2001-2008. In these case reports we elaborate on the therapeutic use of rivastigmine. During off-label rivastigmine use, patients showed minimal further cognitive decline, specifically with respect to frontal defects. However, larger studies and trials are necessary to explore the effects of rivastigmine in patients with PSP.

show abstract

Characteristics and Symptom Management of Progressive Supranuclear Palsy: A Multidisciplinary Approach

Cited by 10 publications

References 0 publications

Progressive Supranuclear Palsy

Progressive Supranuclear Palsy

Amyotrophic Lateral Sclerosis–Plus Syndrome With TAR DNA-Binding Protein-43 Pathology

Progressieve Supranucleaire Verlamming. Interventie middels acetylcholineesteraseremmer?

Contact Info

Product

Resources

About